Drug updated on 11/14/2023
|Injection (intravenous: 5 mg/2 mL, 10 mg/4 mL)
| Ongoing and
- Indicated in adults for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class.
- Indicated in adults for treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.
Product Monograph / Prescribing Information
|Barhemsys (amisulpride) Prescribing Information.
|Acacia Pharma Inc. Indianapolis, IN
Systematic Reviews / Meta-Analyses
|Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis.
|Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis. Hum Psychopharmacol.
|Efficacy of amisulpride on postoperative nausea and vomiting: a systematic review and meta-analysis.
|European Journal of Clinical Pharmacology
|Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta‐analysis.
|Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis.
|Cochrane Database of Systematic Reviews
Clinical Practice Guidelines
|Fourth consensus guidelines for the management of postoperative nausea and vomiting.
|Anesthesia & Analgesia